| Full Name | Vituity |
|---|---|
| Speciality | Internal Medicine |
| Location | 2700 Nw Stewart Pkwy, Roseburg, Oregon |
| Authorized Official Name and Position | David Birdsall (C.O.O./VP) |
| Authorized Official Contact | 5103502600 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Vituity 1601 Cummins Dr Ste D Modesto CA 95358-6411 Ph: (510) 350-2666 | Vituity 2700 Nw Stewart Pkwy Roseburg OR 97471-1281 Ph: (541) 673-0611 |
| NPI Number | 1063833960 |
|---|---|
| Provider Enumeration Date | 12/18/2013 |
| Last Update Date | 06/23/2021 |
| Medicare PECOS PAC ID | 3678464633 |
|---|---|
| Medicare Enrollment ID | O20140702002722 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063833960 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Christina M Ford |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528057593 PECOS PAC ID: 0547169971 Enrollment ID: I20040107000435 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Derrick J Sorweide |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1497721625 PECOS PAC ID: 0345233086 Enrollment ID: I20040511000805 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Kurt A Brickner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1023092178 PECOS PAC ID: 5991788853 Enrollment ID: I20040610001563 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Joseph M Black |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1578524377 PECOS PAC ID: 6103895677 Enrollment ID: I20040930000988 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Steven A Blum |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1619990108 PECOS PAC ID: 6305945833 Enrollment ID: I20071022000800 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Anandita Tiwari |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992775092 PECOS PAC ID: 0648359729 Enrollment ID: I20080430000477 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Wilson Gutierrez |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1962694802 PECOS PAC ID: 0345318911 Enrollment ID: I20081009000174 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Jeffrey E Frank |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1639128895 PECOS PAC ID: 3476598491 Enrollment ID: I20081106000311 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Sarah L Agsten |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1104803691 PECOS PAC ID: 6709773591 Enrollment ID: I20090209000638 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Jun Beom Kwon |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750499513 PECOS PAC ID: 1052465341 Enrollment ID: I20090820000818 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Hennie Tambot Abrio |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891925129 PECOS PAC ID: 6305991159 Enrollment ID: I20090901000208 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Donald Stoddard |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1205818663 PECOS PAC ID: 9032259395 Enrollment ID: I20091216000659 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Siobhan A Oreilly |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1053395160 PECOS PAC ID: 7315088002 Enrollment ID: I20091231000486 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Heidi Beery |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1164627667 PECOS PAC ID: 3476686676 Enrollment ID: I20100809000100 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Nathaniel S Brigham |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1851362578 PECOS PAC ID: 5991991143 Enrollment ID: I20101130000525 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Warren I Okuns |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134385461 PECOS PAC ID: 5698949717 Enrollment ID: I20111129000298 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Mukesh K Thawani |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1174716427 PECOS PAC ID: 5890832810 Enrollment ID: I20120216000232 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Susan M Rundle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578654232 PECOS PAC ID: 3476551615 Enrollment ID: I20120220000261 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Jolanta S Olson |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1346244043 PECOS PAC ID: 6204924962 Enrollment ID: I20120518000182 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Keneilwe Tlaang-setilo |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1851698757 PECOS PAC ID: 0941451488 Enrollment ID: I20121110000125 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Miguel Di Francisco |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1902091192 PECOS PAC ID: 6305921248 Enrollment ID: I20130206000451 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Preeti Satyanarayana |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1063641744 PECOS PAC ID: 2264674795 Enrollment ID: I20130813000988 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Sandesh Pandit |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770781031 PECOS PAC ID: 1658558705 Enrollment ID: I20131004000296 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Christopher K Kwock |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1619103553 PECOS PAC ID: 2567627276 Enrollment ID: I20140721000407 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Samantha Mason |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1639470529 PECOS PAC ID: 0446412589 Enrollment ID: I20140822000784 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Tanja Epley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1336119635 PECOS PAC ID: 9436212230 Enrollment ID: I20140925000324 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Allen D Hack |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750346482 PECOS PAC ID: 2062308158 Enrollment ID: I20150701002920 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Desmond Jy Wah |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1366673568 PECOS PAC ID: 5496901787 Enrollment ID: I20150826002351 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Hooman Hajian |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952512329 PECOS PAC ID: 5294990974 Enrollment ID: I20151005002793 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Laurentiu Istrate |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1437416179 PECOS PAC ID: 5597990630 Enrollment ID: I20151006003088 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Amy Kalina |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104025071 PECOS PAC ID: 7416080577 Enrollment ID: I20151208002660 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Robert E Moss |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174567804 PECOS PAC ID: 5991796740 Enrollment ID: I20151215000910 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | George J. Moussally |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013261973 PECOS PAC ID: 6507010600 Enrollment ID: I20160909001883 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Neha L Jain |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1316387582 PECOS PAC ID: 6901117654 Enrollment ID: I20160912000652 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Ernest O Kanu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1437261179 PECOS PAC ID: 2264411479 Enrollment ID: I20160913000776 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Ovais Khan |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1366871493 PECOS PAC ID: 8921396045 Enrollment ID: I20161005001486 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Luis E Leyton-gonzalez |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013911601 PECOS PAC ID: 8022047174 Enrollment ID: I20170310001373 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Monique Nicole Schwartz |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1952517682 PECOS PAC ID: 1658496369 Enrollment ID: I20170524002405 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Pushpinder Singh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457853103 PECOS PAC ID: 9032473624 Enrollment ID: I20180507002636 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Rishi Saigal |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1467831016 PECOS PAC ID: 9436407392 Enrollment ID: I20180808003822 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Jonathan N Waller |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1801324264 PECOS PAC ID: 0840569133 Enrollment ID: I20200925000900 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Nathan James Andrews |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730685678 PECOS PAC ID: 5294086922 Enrollment ID: I20210824002002 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Brooks Ashworth Smallwood |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1841842184 PECOS PAC ID: 2860875598 Enrollment ID: I20220812002773 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
| Provider Name | Megan Sturdy |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1033590997 PECOS PAC ID: 3173882958 Enrollment ID: I20230608001700 |
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
News Archive
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.
Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.
While timely care can reduce stress among breast cancer patients about their condition, the drive for expediency should not compromise other factors important to care, such as safety, effectiveness, efficiency, and equity, according to new research findings published in the April issue of the Journal of the American College of Surgeons.
If you're going to Oktoberfest next month to enjoy the delights of German beer, you might get more than you bargained for. New research has revealed the extent to which German beers may be contaminated by foreign substances, most notably, microplastics.
› Verified 8 days ago
A.k. Gombart M.d.p.c Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 532 W Umpqua St, Roseburg, OR 97470 Phone: 541-673-0133 | |
Roseburg Clinic Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2750 W Harvard Ave, Roseburg, OR 97471 Phone: 541-673-8988 Fax: 541-672-8103 | |
Douglas Medical Clinic Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1813 W Harvard Ave, Suite 201, Roseburg, OR 97470 Phone: 541-440-6390 Fax: 541-440-6392 | |
Laurence M Sharp Do Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1813 W Harvard Ave, Suite 426, Roseburg, OR 97471 Phone: 541-459-1611 Fax: 541-459-5741 | |
Bestmed Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1740 Nw Goetz Street, Roseburg, OR 97471 Phone: 541-672-4885 Fax: 541-672-4782 | |
Cow Creek Health & Wellness Ctr Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2589 Nw Edenbower Blvd, Roseburg, OR 97471 Phone: 541-672-8533 Fax: 855-670-1791 | |
Gordon F. Rose, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 544 W Umpqua St Ste 104, Roseburg, OR 97470 Phone: 541-673-3334 Fax: 541-673-0814 |